Searched for
PBMS
US debt crisis: Mark Cuban warns America’s $38 trillion debt is tied to broken healthcare pricing - here’s his solutionMark Cuban warns about US debt crisis: Cuban argues that overhauling healthcare, particularly insurance and drug pricing, can significantly...- Financials still in play, but rotation towards quality largecaps underway: Jigar MistryJigar Mistry of Buoyant Capital favors healthcare, materials, chemicals, and banking sectors, preferring large-cap private banks over PSU b...
- Generic pharma companies unlikely to be impacted by Trump's order to cut Rx drug prices: ReportA report suggests Indian generic drug companies may not be affected by US President Donald Trump's order. The order aims to lower US prescr...
- Biocon betting big on new product launches for growthBiocon aims to grow through new product launches in generics and biosimilars, bolstered by the Viatris acquisition. This strategy integrate...
- UnitedHealth, the company that employed slain CEO Brian Thompson, allegedly overcharged some cancer patients by more than 1,000% for their medicationsUnitedHealth, in which slain CEO Brian Thompson was employed, has been allegedly accused of overcharging patients suffering from dangerous ...
- White House meets with UnitedHealth CEO over hackThe meeting was the first to bring together providers such as hospitals and payers such as health insurers, said a spokesperson from the De...
- Using current rally to shift more into largecaps and to fully deploy new cash: Jigar Mistry“If we take 25% of a drawdown as a particular pullback or start of a new cycle, then arguably we are in the second best smallcap rally sinc...
- Quite comfortable about level of debt currently on our books: Shreehas Tambe, Biocon BiologicsSo from that point of view in the sense, of course, we expect it to be neutral or maybe slightly better but more or less neutral. On the ma...
- Biocon Biologics set to reap biosimilar insulin glargine opportunity in USDrugmaker Biocon is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and pr...
- Biocon's interchangeable biosimilar Insulin glargine added on Express Scripts’ largest formulary in USThe listing is expected to boost Biocon's biosimilar business, as inclusion of Semglee on Express Scripts' NPF will allow pharmacies to sub...
- For US-facing pharma cos, Q2 & Q3 likely to be soft quarters: Nithya Balasubramanian“For the next couple of quarters, on a YoY basis, I am expecting that generic price deflation could be higher in the second as well as the ...
- Biocon’s $1-bn target for biologics biz achievable by FY22: Kiran Mazumdar ShawIn the next 10 years, there is great opportunity for cos that want to play in biosimilars.
- Piramal arm acquires Adaptive for potential payment of$24.5 millionA US-based subsidiary of Piramal Enterprises has acquired Adaptive Software for a total potential consideration of USD 24.5 million.
- Sanofi bets on dengue vaccine, 5 other drugs to bolster India playFrench co plans to bring raft of innovative products, including preventive dengue vaccine; move may improve company’s prospects over its ri...
- Pfizer marketing may hit Ranbaxy’s profit from low-cost lipitor versionLate last year, Pfizer started offering ‘co-pay’ programmes which lowered out of pocket payment by insured patients to $4 a month for a Lip...
Load More
